SCHEMBL6085366

SCHEMBL6085366

CCCCC(C)(C)C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3c(C)ccc(C(C)C)c3o2)cc1

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CEPT1 Q9Y6K0 10/20 0.34
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
P2RY1 P47900 1/20 0.32
CETP P11597 4/20 0.32
DGAT1 O75907 1/20 0.32
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
XBP1 P17861 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086048 0.88 CEPT1 (0.33) CEPT1CETPDGAT1KDM4EALDH1A1
SCHEMBL6084636 0.80 CEPT1 (0.34) CEPT1KMT2ACETPCNR1CNR2
SCHEMBL6085715 0.78 MAPT (0.49) CEPT1MEN1KMT2ACETPKDM4E
SCHEMBL6086379 0.76 CETP (0.40) CEPT1MEN1KMT2ATDP1CETP
SCHEMBL6086210 0.76 CETP (0.41) CEPT1MEN1KMT2ACETPKDM4E
SCHEMBL6084760 0.76 MAPT (0.44) MEN1KMT2AALDH1A1MAPT
SCHEMBL6085964 0.76 CEPT1 (0.52) CEPT1CETPMAPT
SCHEMBL6085797 0.74 NPC1 (0.42) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6086910 0.72 HSP90AA1 (0.39) KMT2AALDH1A1
SCHEMBL6084903 0.71 MEN1 (0.44) MEN1KMT2ATDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CEPT1 2798/4885MEN1 2891/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.